Recce Pharmaceuticals bolsters cash position with A$3.67 million tax refund ahead of Phase 3 milestones
Panmure Liberum says wine takeover exposes deep value at Naked and Virgin
Recce raises A$4M as it advances anti-infective trials and commercial licensing plans; another $4M to come in SPP
Nasdaq set to take another hit from rotation out of tech before quarter-end
Data layer emerges as the defining battleground of the AI revolution
Recce secures path to MENA commercialisation - ICYMI
Canada enters technical recession as GDP contracts for second straight quarter
Recce Pharmaceuticals advances US Army burn wound program and Indonesia Phase 3 trial in March quarter
Recce clears Indonesian Phase 3 site inspection as diabetic foot infection trial advances
Apple after Cook: what the hardware era means for investors
CRISM Therapeutics shares jump on positive prostate cancer drug delivery data
SEEEN shares climb as AIM company acquires profitable video platform MEDIAL for £1.2m
Roblox price target cut on slowing engagement, demanding 2026 guidance
Inside Biotech: Recce Pharmaceuticals advances late-stage push in antibiotic resistance fight
Recce expands patent footprint with Brazil grant for anti-infectives platform
Simply Good Foods upgraded by Jefferies on Quest brand’s momentum amid 'protein megatrend'
Recce to host webinar on Phase 3 trial and anti-infective pipeline update
Shore Capital downgrades AstraZeneca as R&D spending dampens earnings trajectory
Recce signs second US Army research agreement for RECCE® 327 burn gel
Small Cap Watch: Small cap markets slide, but as companies push ahead with exploration and R&D
Recce Pharmaceuticals banks A$5.3m cash refund from the ATO
Tech Bytes: DroneShield bucks the tech sell-off with $49.6m European military deal
Recce secures A$85M Advanced Overseas Finding to support global anti-infective R&D
FTSE 100 Live: Stocks open lower after weak UK jobs data, defence and oil drop
FTSE 100 Live: Blue-chip index flat; banks and builders on the march
Hong Kong patent grant strengthens Recce Pharmacueticals’ regional strategy and IP footprint
Naver Financial to buy Upbit owner Dunamu in $10bn crypto deal
UBS is bullish on Ceres, if the fuel cell firm can land at least one new partner
Recce’s inhaled R327 shows potent antibacterial effect in preclinical pneumonia study
Recce mourns the loss of its founder and pioneer Dr Graham JH Melrose